Initially intended to fill a therapeutic void, the FDA's pathway for single-arm trials in BCG-unresponsive bladder cancer has led to numerous approvals. This success has created a new problem: a crowded market of expensive drugs with weak comparative data, making rational treatment selection difficult.

The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

For antibody-drug conjugates (ADCs) to make a meaningful impact in prostate cancer, the clinical development bar is exceptionally high. Merely showing activity in late-line settings is insufficient; the true measure of success is demonstrating superiority over the established chemotherapy standard, docetaxel.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

The widely used and effective off-label combination of gemcitabine/docetaxel is rarely administered in community settings. The inexpensive drugs and long patient chair time make it a financial loss for these practices, creating an economic, not clinical, barrier to a viable treatment.

Across dozens of clinical trials in metastatic castration-resistant prostate cancer (mCRPC) that have randomized an experimental agent against the chemotherapy docetaxel, Rucaparib is the first and only one to demonstrate a statistically significant improvement, highlighting the difficulty of improving on this standard of care.

The effective, inexpensive standard of care, gemcitabine-docetaxel ('gemdose'), is rarely used in US community practices because it is unprofitable. Clinicians openly admit to choosing more expensive, reimbursed drugs to maintain financial viability, creating a stark divide with academic centers.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Designing a randomized trial to compare surgery versus systemic therapy alone is nearly impossible. A previous attempt, the SPARE study, failed to recruit because clinicians and patients already had strong pre-existing opinions on the best course of action, a bias that persists today.